Challenges for pharmaceutical industry: new partnerships for sustainable human health.
نویسنده
چکیده
The healthcare burden is increasing in both the developed and the developing world and there is widespread acceptance that the historical pharmaceutical business model is not sustainable. In order to meet the healthcare challenge, companies and academia need to develop new business models to increase the probability of success and decrease the cost of failure. New partnerships have already emerged in the area of neglected diseases and other models for diseases of the developed world are emerging.
منابع مشابه
Addressing NCDs: Penetration of the Producers of Hazardous Products into Global Health Environment Requires a Strong Response; Comment on “Addressing NCDs: Challenges From Industry Market Promotion and Interferences”
Timely warnings and examples of industry interference in relation to tobacco, alcohol, food and breast milk substitutes are given in the editorial by Tangcharoensathien et al. Such interference is rife at national levels and also at the global level. In an era of ‘private public partnerships’ the alcohol and food industries have succeeded in insinuating themselves into the global health environ...
متن کاملSearching for the Right to Health in the Sustainable Development Agenda; Comment on “Rights Language in the Sustainable Development Agenda: Has Right to Health Discourse and Norms Shaped Health Goals?”
The United Nations (UN) Sustainable Development Agenda offers an opportunity to realise the right to health for all. The Agenda’s “interlinked and integrated” Sustainable Development Goals (SDGs) provide the prospect of focusing attention and mobilising resources not just for the provision of health services through universal health coverage (UHC), but also for addressing the underlying social,...
متن کاملPublic-private partnerships as driving forces in the quest for innovative medicines
UNLABELLED BACKGROUND Despite progress in translational research, we are still falling short in developing the innovative medicines required to address major public health needs. Furthermore, the failure rate, time, and cost required for registration of a new drug are pushing the economics of the industry to the breaking point. New models of drug development based on collaborative endeavours...
متن کاملPharmaceutical industry, non-communicable diseases and partnerships: More questions than answers
When 21 biopharmaceutical companies recently launched the Access Accelerated Initiative (AAI) on prevention and care for non-communicable diseases (NCD) [1] in Davos, Switzerland, it was described as a ‘global, multi-stakeholder collaboration’. The need for partnership is included in the Sustainable Development Goals (SDG). SDG 17 aims to “Revitalize the global partnership for sustainable devel...
متن کاملChallenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Industrial renewal in the bio/nanopharma sector is important for the long term strength of the Australian economy and for the health of its citizens. A variety of factors, however, may have caused inadequate attention to focus on systematically promoting domestic generic and small biotechnology manufacturers in Australian health policy. Despite recent clarifications of 'springboarding' capacity...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Philosophical transactions. Series A, Mathematical, physical, and engineering sciences
دوره 369 1942 شماره
صفحات -
تاریخ انتشار 2011